MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-03-2025
IDEXX Laboratories Total Assets 2011-2025 | IDXX
Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.Main categories of assets
Current assets (used within one year):
- Cash and cash equivalents
- Accounts receivable (amounts owed by customers)
- Inventory of goods, raw materials, and supplies
- Short-term investments
- Fixed assets (buildings, machinery, equipment)
- Intangible assets (brands, patents, software)
- Long-term investments
- Goodwill (reputational value from mergers)
Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.
Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.
Annual Total Assets IDEXX Laboratories
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3.29 B | 3.26 B | 2.75 B | 2.44 B | 2.29 B | 1.83 B | 1.54 B | 1.71 B | 1.53 B | 1.47 B | 1.38 B | 1.23 B | 1.1 B | 1.03 B |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 3.29 B | 1.03 B | 1.92 B |
Quarterly Total Assets IDEXX Laboratories
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3.39 B | 3.33 B | 3.21 B | 3.29 B | 3.35 B | 3.41 B | 3.35 B | 3.26 B | 3.09 B | 2.87 B | 2.81 B | 2.75 B | 2.64 B | - | 2.59 B | 2.44 B | 2.39 B | 2.41 B | 2.33 B | 2.29 B | 2.29 B | 2.29 B | 2.29 B | 1.83 B | 1.83 B | 1.83 B | 1.83 B | 1.54 B | 1.54 B | 1.54 B | 1.54 B | 1.71 B | 1.71 B | 1.71 B | 1.71 B | 1.53 B | 1.53 B | 1.53 B | 1.53 B | 1.47 B | 1.47 B | 1.47 B | 1.47 B | 1.38 B | 1.38 B | 1.38 B | 1.38 B | 1.23 B | 1.23 B | 1.23 B | 1.23 B | 1.1 B | 1.1 B | 1.1 B | 1.1 B | 1.03 B | 1.03 B | 1.03 B | 1.03 B |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 3.41 B | 1.03 B | 1.96 B |
Total Assets of other stocks in the Diagnostics research industry
| Issuer | Total Assets | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Brainsway Ltd.
BWAY
|
94.3 M | $ 17.13 | 1.66 % | $ 99.4 M |  Israel |
 |
Centogene N.V.
CNTG
|
77.2 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
DarioHealth Corp.
DRIO
|
96.4 M | $ 12.15 | 2.14 % | $ 345 M | Israel |
 |
DexCom
DXCM
|
6.26 B | $ 66.06 | -1.34 % | $ 25.5 B |  USA |
|
Akumin
AKU
|
1.77 B | - | -17.87 % | $ 25.9 M |  Canada |
 |
Exact Sciences Corporation
EXAS
|
5.93 B | $ 101.57 | 0.07 % | $ 18.8 B | USA |
 |
Burning Rock Biotech Limited
BNR
|
2.28 B | $ 16.0 | 1.59 % | $ 172 M |  China |
 |
Accelerate Diagnostics
AXDX
|
65 M | - | -61.36 % | $ 2.46 M | USA |
 |
Biocept
BIOC
|
30.9 M | - | -13.05 % | $ 7.29 M | USA |
 |
BioNano Genomics
BNGO
|
76.7 M | $ 1.56 | -3.7 % | $ 1.98 M | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
235 M | - | - | $ 562 M |  Britain |
 |
Castle Biosciences
CSTL
|
531 M | $ 38.95 | 0.82 % | $ 1.08 B | USA |
 |
Chembio Diagnostics
CEMI
|
62.6 M | - | 0.22 % | $ 16.8 M | USA |
 |
Danaher Corporation
DHR
|
77.5 B | $ 227.29 | 0.42 % | $ 166 B | USA |
 |
Fulgent Genetics
FLGT
|
1.22 B | $ 26.94 | -0.74 % | $ 815 M | USA |
 |
Global Cord Blood Corporation
CO
|
8.53 B | - | - | $ 399 M | China |
 |
Mettler-Toledo International
MTD
|
3.24 B | $ 1 408.65 | 1.08 % | $ 29.9 B |  Schweiz |
 |
Fluidigm Corporation
FLDM
|
325 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
20.8 M | - | - | $ 7.1 B |  Australia |
 |
NeoGenomics
NEO
|
1.64 B | $ 12.15 | 2.53 % | $ 1.54 B | USA |
 |
Neogen Corporation
NEOG
|
3.44 B | $ 6.84 | -0.36 % | $ 1.48 B | USA |
 |
Genetron Holdings Limited
GTH
|
975 M | - | 0.12 % | $ 80.1 M | China |
 |
DermTech
DMTK
|
122 M | - | -11.32 % | $ 2.94 M | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
4.18 B | - | - | $ 10.7 B | USA |
 |
CareDx, Inc
CDNA
|
467 M | $ 19.9 | -3.21 % | $ 1.07 B | USA |
 |
Pacific Biosciences of California
PACB
|
1.75 B | $ 2.12 | - | $ 538 M | USA |
 |
Celcuity
CELC
|
245 M | $ 101.74 | -3.33 % | $ 4.01 B | USA |
 |
Enzo Biochem
ENZ
|
85.8 M | - | -8.98 % | $ 14.8 K | USA |
 |
Anixa Biosciences
ANIX
|
21.6 M | $ 3.35 | -6.42 % | $ 107 K | USA |
 |
Koninklijke Philips N.V.
PHG
|
29 B | $ 26.46 | -0.62 % | $ 20 B |  Niderland |
 |
Co-Diagnostics
CODX
|
95.3 M | $ 0.3 | -13.39 % | $ 8.8 M | USA |
 |
Precipio
PRPO
|
18.1 M | $ 24.67 | -1.2 % | $ 32 M | USA |
 |
Quidel Corporation
QDEL
|
1.87 B | $ 28.82 | 0.07 % | $ 1.21 B | USA |
 |
IQVIA Holdings
IQV
|
26.9 B | $ 224.13 | 0.84 % | $ 40.6 B | USA |
 |
QIAGEN N.V.
QGEN
|
5.69 B | $ 45.14 | -0.21 % | $ 10 B | Niderland |
 |
Guardant Health
GH
|
1.49 B | $ 103.55 | 1.45 % | $ 12.7 B | USA |
 |
Aspira Women's Health
AWH
|
17.4 M | - | -6.19 % | $ 10.5 M | USA |
 |
Sotera Health Company
SHC
|
3.07 B | $ 16.76 | -0.42 % | $ 4.74 B | USA |
 |
Soleno Therapeutics
SLNO
|
331 M | $ 49.79 | -4.25 % | $ 2 B | USA |
 |
Heska Corporation
HSKA
|
586 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
17.8 M | - | -20.0 % | $ 1.06 M | USA |
 |
Thermo Fisher Scientific
TMO
|
97.3 B | $ 574.27 | 0.46 % | $ 219 B | USA |
 |
Illumina
ILMN
|
6.3 B | $ 134.66 | -0.16 % | $ 21.4 B | USA |
 |
Charles River Laboratories International
CRL
|
7.53 B | $ 197.59 | 2.36 % | $ 10.2 B | USA |
 |
Trinity Biotech plc
TRIB
|
103 M | $ 0.96 | -10.6 % | $ 61.9 M |  Irlanda |
 |
Twist Bioscience Corporation
TWST
|
642 M | $ 31.39 | 1.47 % | $ 1.88 B | USA |
 |
Quotient Limited
QTNT
|
220 M | - | -11.32 % | $ 1.1 M | Schweiz |
 |
Quest Diagnostics Incorporated
DGX
|
16.2 B | $ 184.04 | 0.81 % | $ 20.4 B | USA |
|
Biodesix
BDSX
|
97.2 M | $ 7.63 | -2.8 % | $ 989 M | USA |
 |
Myriad Genetics
MYGN
|
1.03 B | $ 7.07 | -2.01 % | $ 641 M | USA |